Antiphospholipid Antibody Induced by Nivolumab. (11th January 2018)

• Record Type: Journal Article
• Authors: Aburahma, Ahmed; Aljariri Alhesan, Nour; Elounais, Farah; Abu Sitta, Emad
• Other Names: Gentile Massimo Academic Editor.
• Is Part Of: Case reports in hematology. Volume 2018(2018)
• Publication Date: 2018-01-11
• Subjects: Hematology -- Periodicals; Hematology -- Case studies -- Periodicals; Blood -- Diseases -- Periodicals; Hematology; Hematologic Diseases; Blood -- Diseases; Hematology; Electronic journals; Periodicals; Case studies; Periodicals; Case Reports; Fulltext; Internet Resources; Periodicals; 616.15
• DOI: 10.1155/2018/3106852
• Languages: English
• ISSNs: 2090-6560

Abstract

Abstract : Nivolumab is a monoclonal antibody against the programmed death protein 1 and is used for patients with advanced melanoma. It is associated with potentially immune-related adverse events, including disorders of the skin, GI tract, and the thyroid; these disorders were successfully treated with prednisone and infliximab. Other immunotherapeutic agents were observed to induce the formation of antiphospholipid antibody (APA) including α -interferon and interleukin-2. We present a case of APA development after the third dose of nivolumab in a 71-year-old male with advanced melanoma. The APA was detected after finding a prolonged aPTT; the lupus anticoagulant assay tested positive. The patient was treated with prednisone but, unfortunately, he expired a few days later.